Shire (SHPG) Announces $53 Billion AbbVie (ABBV) Takeover Offer

NEW YORK (TheStreet) -- AbbVie  (ABBV) fell in pre-market trading on Monday after Irish biopharmaceutical company Shire  (SHPG) announced it would recommend a $53 billion takeover offer from the Humira maker, which could pave the road for one of the sector's largest mergers.

Chicago-based AbbVie offered a cash-and-stock deal equivalent to $91.10 a share for Shire over the weekend, which surpassed its previous offer of $51 billion. If completed, the deal would allow AbbVie to save millions of dollars in taxes via reincorporation in Britain, which has lower tax rates. Shire's headquarters are on the British island of Jersey.

Shire announced its shareholders would own approximately 25% of the combined AbbVie under the deal.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

British regulators set a Friday, July 18 deadline to complete the deal. If it does not happen by that date, then AbbVie must abstain from negotiations for six months.

AbbVie was down 2.73% to $53.46 in pre-market trading, while Shire was up 1.61% to $253.06.

ABBV Chart ABBV data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

AbbVie Is Likely to Correct: Book Some Profits

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst